Co-Authors
This is a "connection" page, showing publications co-authored by Ke Lan and Hualiang Jiang.
Connection Strength
0.617
-
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. Virol Sin. 2020 Dec; 35(6):725-733.
Score: 0.447
-
Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell. 2021 Jan; 12(1):76-80.
Score: 0.058
-
Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell. 2020 Nov 09.
Score: 0.057
-
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell. 2020 10; 11(10):723-739.
Score: 0.056